Cargando…
Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study
Aims: To assess SARS-CoV-2 seroprevalence over the first epidemic wave in the canton of Geneva, Switzerland, as well as risk factors for infection and symptoms associated with IgG seropositivity. Methods: Between April and June 2020, former participants of a representative survey of the 20–74-year-o...
Autores principales: | Richard, Aude, Wisniak, Ania, Perez-Saez, Javier, Garrison-Desany, Henri, Petrovic, Dusan, Piumatti, Giovanni, Baysson, Hélène, Picazio, Attilio, Pennacchio, Francesco, De Ridder, David, Chappuis, François, Vuilleumier, Nicolas, Low, Nicola, Hurst, Samia, Eckerle, Isabella, Flahault, Antoine, Kaiser, Laurent, Azman, Andrew S., Guessous, Idris, Stringhini, Silvia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808008/ https://www.ncbi.nlm.nih.gov/pubmed/34664529 http://dx.doi.org/10.1177/14034948211048050 |
Ejemplares similares
-
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study
por: Stringhini, Silvia, et al.
Publicado: (2020) -
Forgoing healthcare during the COVID-19 pandemic in Geneva, Switzerland – A cross-sectional population-based study
por: Menon, Lakshmi Krishna, et al.
Publicado: (2022) -
Socio-economic determinants of SARS-CoV-2 infection: Results from a population-based cross-sectional serosurvey in Geneva, Switzerland
por: Santa-Ramírez, Hugo-Alejandro, et al.
Publicado: (2022) -
Specchio-COVID19 cohort study: a longitudinal follow-up of SARS-CoV-2 serosurvey participants in the canton of Geneva, Switzerland
por: Baysson, Helene, et al.
Publicado: (2022) -
Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021
por: Stringhini, Silvia, et al.
Publicado: (2021)